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Abstract— Genomic knowledge has become a popular research field in bioinformatics biological process that providing further 
biological process information. Many methods have been done to address the issues of high data throughput due to increased use of 
microarray technology. However, it is still not able to determine the appropriate diseases accurately. This is because of existing non-
informative genes that could be included in the analysis of context-specific data like cancer gene expression data, which affect the 
classification performance. This study proposed a pathway-based analysis for gene classification. Pathway-based analysis enables 
handling microarray data in order to improve biological interpretation of the analysis outcome. Secondly, Support Vector Machine 
with Least Absolute Shrinkage and Selection Operator algorithm (SVM-LASSO) is proposed, which to find informative genes for 
each pathway to ensure efficient gene selection and classification in every pathway. Experiments are done using lung cancer dataset 
and breast cancer dataset that widely used in cancer classification area. A stratified 10-fold cross validation is implemented to 
evaluate the performance of the proposed method in terms of accuracy, specificity, and sensitivity. Moreover, biological validation has 
been done on the selected genes based on biological literature and biological databases. Next, the results from the proposed methods 
are compared with the previous study throughout all the data sets in terms of performance. As a conclusion, this research finding can 
contribute in biology area especially in cancer classification area. 
 
Keywords— genomic knowledge; gene analysis; microarray technology; pathway-based analysis; support vector machine; LASSO; 
10-fold cross-validation; cancer classification 
 
 
I. INTRODUCTION 
In Genome database, there are many genes stored with 
different types, features, and functions example gene 
expression data.  Some of the biological knowledge need to 
identify such as gene structure, gene function, and gene 
expression. From the features, the genes can determine 
whether active, hyperactive or silent in normal or cancerous 
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tissues. Also, the genes need to be classified whether it is a 
normal gene or abnormal gene that can cause diseases such 
as cancer diseases. Gene selection process is involved during 
pathway-based analysis in order to identify the subset of 
informative genes. This process eliminates irrelevant and 
redundant genes that can lead to misleading of classification. 
It is important to overcome the high-throughput data 
problems, which contain several noise genes that hold less 
information related cancer diseases.  
Microarray is one of the lab approaches to measure gene 
expression. There are another lab approaches such as Serial 
Analysis of Gene Expression (SAGE) that are based on 
isolation of unique sequence tag of mRNAs with a 
combination of long sequence serially for sequencing [1]. 
Microarray technology capable in analyse several thousand 
of genes simultaneously compared to SAGE. In microarray 
area, there are many types of microarray such as DNA 
microarray, tissue microarray, protein microarray, and etc. In 
a study of complex diseases and their causes, DNA 
microarray data had been used widely. Therefore, pathway 
knowledge into microarray data has been favoured by 
researchers in the area of bioinformatics owing to the 
improved biological interpretation of the analysis outcome 
Thus, the pathway-based analysis for gene classification is 
generally explained.  
Recently, pathway-based analysis got a lot of attention in 
the genomic research area. This is because pathway-based 
analysis method capable in detect subtle compared to single-
gene analysis [2-3]. In fact, the pathway analysis or 
pathway-based analysis had been widely used in research 
areas such as analysis of gene sets, metabolic pathway 
analysis and etc. [4]. In past few years, the focus has shifted 
to the pathway-based analysis that capable used large-scale 
omics data in order to improve the biological interpretations, 
which is important to the identification of complex diseases 
like cancers [5]. Commonly, pathway analysis has always 
been used to know signalling or metabolic pathways are 
activated under certain experimental condition. This method 
can be used to classify gene in via networks, pathways or 
paths where many linked components have been induced. 
In this research, Support Vector Machine (SVM) had been 
implemented. Machine learning is an artificial intelligence 
technique that concern about design and development of an 
algorithm that allows the computer to learn behaviours based 
on the empirical data. SVM is one of the machine learning 
that widely used and a discriminative classifier formally 
defined by a separating hyperplane. In other words, given 
labelled training data (supervised learning), the algorithm 
outputs an optimal hyperplane which categorizes new 
examples. Recently, the previous researcher stated a hybrid 
variable selection or classification approach that is based on 
linear combinations of the gene expression profiles could 
maximize an accuracy measure is shown by receiver 
operating characteristics curve [6]. There are previous 
methods that have been used to select and classify the gene, 
but there still have limitation. 
Generally, Least Absolute Shrinkage and Selection 
Operator (LASSO) is a technique for variable selection, 
especially when dealing with high dimensional data. It 
involves penalizing the absolute size of the regression 
coefficients. LASSO technique has been investigating for 
computing efficient model descriptions of nonlinear systems. 
It minimizes the residual sum of squares by the addition of a 
penalty term on the parameter vector of the traditional 
minimization problem. LASSO structure perform detection 
method was evaluated by using it to estimate the structure of 
a nonlinear polynomial model. 
II. MATERIALS AND METHODS 
Microarray is one of the lab approaches to measure gene 
expression. There are another lab approaches such as Serial 
Analysis of Gene Expression (SAGE) that are based on 
isolation of unique sequence tag of mRNAs with a 
combination of long sequence serially for sequencing. 
Microarray technology capable in analyse several thousand 
of genes simultaneously compared to SAGE. In microarray 
area, there are many types of microarray such as DNA 
microarray, tissue microarray, protein microarray and etc. In 
a study of complex diseases and their causes, DNA 
microarray data had been used widely. 
LASSO is one of the linear regression models that used 
for variable selection when dealing with high dimensional 
data. It can identify the important variables by adding an L1 
penalty to unusual regression objective function. LASSO 
also the best techniques in gene classification because it can 
improve the accuracy when selecting the variable.  Because 
the data are complex and multivariate, it is important to 
develop a technique to detect systematic signals in gene 
expression patterns. Based on [6], LASSO is the suitable 
technique to solve the problem of variable selection and 
classification. Some of the variables will be estimated to be 
exactly zero to present genes that have no discriminatory 
power between two classes, while those genes with non-zero 
coefficients will present genes that can separate classes of 
tumour successfully. LASSO is used to greatly reduce the 
number of candidate pattern. The computational algorithm 
can handle an extremely large number of unknowns 
simultaneously.  
LASSO is known to have automatic variable selection 
ability in linear regression analysis. LASSO is used to select 
the most informative genes for representing the probability 
of an example being positive as a linear function of the gene 
expression data. LASSO is more capable of selecting the 
important genes classification. Besides, LASSO also used in 
linear regression and also one of the most widely used 
techniques for robust regression and sparse estimation. 
Linear regression is a commonly used approach in 
bioinformatics. There are some challenges of linear 
regression, that is the number of regression weights needed 
to be determined is often at least one order of magnitude 
larger than a number of data points. 
The data are (, ), where  (=1,…,) is continuous 
variable. LASSO solution is to optimizing problem of 
minimizing 
where β=(β1,…,βp) and  ≥ 0 is a penalty term. This is 
the way LASSO estimate to utilized is an L1constraint. An 
alternative way of formulating the above formulae is to 
minimizing. LASSO based classifiers have better 
performance in terms of average testing error. This shows 
(1) 
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LASSO is more efficient at picking informative genes for 
linear classifiers. 
An alternative way of formulating the above formulae is 
by minimization. LASSO based classifiers have better 
performance in terms of average testing error. This shows 
LASSO is more efficient at picking informative genes for 
linear classifiers. The pathway-based analysis had been 
proposed with a combination of SVM-LASSO to improve 
the gene selection and classification performance in complex 
gene dataset. The concept of pathway-based analysis is 
analysing the gene expression in a group that related to the 
pathway information. Thus, the gene selection and 
classification has been improved due to the concept. This is 
because the size of gene expression become smaller. Only 
the informative genes that relate with the pathway are 
selected. Fig. 1 shows illustrate of pathway-based analysis 
approach. 
 
 
Fig. 1 Illustrate of pathway-based analysis 
 
Next, each group of pathway will be executed to stratified 
10-fold cross validation for accuracy performance validation. 
In this process, the data will divide into two groups of data 
which is training data set and testing data set. This two type 
of data set is used in support vector machine for the 
classification process. SVM will classify the classes by 
maximizing the margins, and this method is used for 
classification. For improving the selection process, an 
algorithm is implemented in SVM which is Least Absolute 
Shrinkage and Selection Operator. LASSO algorithm can 
control the complexity the size of the gene due to its 
capability in select informative gene automatically. SVM 
classified the gene expressions data in the pathway into their 
classes (e.g., tumor or normal). Next, the activities of this 
research are explained in Table 1 and Fig. 2 shows the 
flowchart of the proposed method. 
In this research, gene expression microarray technologies 
and pathway data are used. The pathway data acts as prior 
biological knowledge where the gene expression data is 
grouped into corresponding gene sets based on the pathway 
data. The development of a computational system for 
classification gene based on cancer diseases creation based 
on Microarray data. Microarray dataset contains thousands 
of spots, and each spot may contain a few million copies of 
identical DNA molecules that uniquely correspond to a gene.  
TABLE I 
EXPLANATION OF ACTIVITIES 
Activities Explanation 
Pre-processing data First, the data set is obtained from 
microarray analysis and undergoes pre-
processing data process. Next, the output 
form pre-processing data are defined as gene 
expression data. Then, gene expression data 
is divided into corresponding pathways 
according to the pathway data. Each pathway 
consists of a subset of gene expression data 
for the genes that associated to the pathway.  
Selection by LASSO The data are selected using a linear 
regression model to identify the informative 
information by reducing the number of gene 
expression. Thus, the noise data like 
uninformative genes are removed in order to 
reduce the complexity of experiment and in 
same time increase the accuracy of pathway 
performance. 
Classification In this research, support vector machine is 
used in the classification process. The data 
are separated based on decision plane where 
the sample has a different class which is a 
tumour and normal in cancer diseases case. 
Rank the pathway Finally, the pathway is rank based on 
accuracy value from higher to lower value. 
From that, the higher accuracy value shows 
that the pathway is more significant to 
targeted phenotype. As this research uses 
stratified 10-fold cross-validation (CV) for 
performance evaluation, after the data 
grouping process, samples from each 
pathway are partitioned based on the 10-fold 
CV requirement. 
 
This experiment was done by using the datasets from 
GSEA and NCBI GEO which consists of lung gene 
expression and breast gene expression based on the previous 
researcher. Most of the researcher using this data to perform 
pathway-based analysis in order to classify the cancer genes. 
Available gene expression data includes Expressed Sequence 
Tags (ESTs), microarray files, and quantitative mass 
spectrometry protein measurements. An estimation of the 
error rate using 10-fold cross-validation was performed. 
This generally gave an error rate between 15-20% for 
various choices, and there are some pre-processing steps for 
the dataset. The remained gene expression is for analysis. In 
addition, the pathway dataset is used to group the gene for 
the classification process. This data will match with pathway 
dataset and placed in one table or file. Genes have different 
name and associate number depend on the chips that used. 
Two gene expression datasets are used in this research. Both 
datasets can be download at http://www.broadinstitute.org/ 
gsea/datasets.jsp and NCBI GEO database. Table 2 shows 
the gene expression data used in this research. 
 
TABLE II 
SUMMARY OF GENE EXPRESSION DATA SET 
Dataset No. of 
Sample 
No. of 
Genes 
Class Ref. 
Lung A 86 7129 2(normal/ tumour) [6] 
Breast 49 22218 3 tumour 
types 
[7] 
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 Fig. 1  Flowchart of proposed method 
III. RESULT AND DISCUSSION 
The result obtain from this study will be compared with 
previous methods and will be discuss in term of average 
accuracy of top 10 pathway and also the relational of gene 
with diseases.  
In this research, gene selection and classification is 
implement by Pathway-based analysis with SVM-LASSO. 
The prediction performance of this functional analysis is 
measured by 10-fold cross validation accuracy and test set of 
correctness. The number of gene selected for each dataset is 
corresponding to the highest value of test set of correctness. 
The result of proposed method for both data sets are shows 
in Table 3. 
According to the findings, Pathway-based analysis with 
SVM-LASSO performs well in prediction since the value 
accuracy of 10-fold cross validation is high and same goes to 
value of test correctness in overall. The differences between 
this two data in term of accuracy is 12%. Same goes to value 
of test correctness that is 1.91%. The result of this research 
are the pathway-based analysis of pathways and gene 
expression data with the application of SVM-LASSO. The 
data used in this re-search include Lung A [7] and Breast [8]. 
The different dataset are used to evaluate the performance of 
proposed method. These dataset are being analyse in term of 
test set correctness, 10-fold cross validation accuracy and 
average genes selected. The result is more significant with 
the implementation of pathway-based analysis as the gene 
expression being grouped followed the pathway dataset. 
Next, the data are analysed by the pathway that stored the 
gene expression value. The following section discusses and 
analysed the result obtained in this research. The comparison 
method between previous researches is presented in Table 4. 
The reading is recorded for five minutes. 
 
TABLE III 
RESULT OF 10-FOLD CROSS-VALIDATION OF TWO DATA SET 
Dataset Number 
of Genes 
Number 
of Sample 
Number 
of 
pathway 
10-fold Cross 
Validation 
Accuracy (%) 
Lung A 7129 86 434 83.21% 
Breast 22218 49 435 60% 
 
TABLE IV 
COMPARISON PERFORMANCE BETWEEN PREVIOUS RESEARCHERS 
Method 10-fold CV accuracy (%) 
Lung A Breast 
Pathway-based with SVM-
LASSO 83.21% 60% 
Pathway-based with Random 
Forest (Chin et al., 2012) 42% 60% 
 
Based on the table above, the accuracy of the proposed 
method is higher than the previous method by using lung 
cancer data. However, the accuracies of breast cancer data 
for both methods are same. This shows the proposed method 
is not performed well in breast cancer data. Thus, the type of 
data used influences the accuracy of classification. Next, the 
selected pathway and genes are continues to biological 
validation.  
 In this section, the selected genes in the pathway 
produced by the proposed method will be validated using 
Genecards. For this process need to be done by manually. 
The pathway is selected and validated, for lung data in Table 
5 and for breast cancer in Table 6. 
In Table 5 above, shows the pathways with highest 
average 10-fold CV accuracy in this research. The top-
ranked pathway is a CDK regulation of DNA replication, 
known as a cyclin-dependent kinase. Although there is no 
proof for the direct relationship of this pathway to lung 
cancer, CDK-containing fractions activated the replication of 
the SV40 virus in cellular extracts [22]. The CDK regulation 
pathway achieves 88.23% accuracy in the 10-fold CV. Next, 
from the proposed method has selected two informative 
genes for the classification.  
Second-ranking goes to Nucleotide sugar metabolism 
pathway. This pathway is related to Galactosemia disease or 
known as an autosomal recessive disorder caused by a defect 
in one of the three enzyme genes for galactose metabolism 
[23]. It also can cause severe growth problems including 
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cataracts. Even though the pathway has higher accuracy in 
10-fold CV, the pathway does not have any proof that 
related to cancer. But, the genes that selected are one of the 
markers in cancer disease.  
 
TABLE V 
PATHWAY FROM SVM-LASSO RANKED BY 10-FOLD CV CLASSIFICATION 
ACCURACY IN LUNG CANCER DATA 
Pathway 10-fold CV 
accuracy (%) 
Selected genes Ref. 
CDK Regulation 
of DNA 
Replication 
88.23 MCM5 
MCM3 
[9]-[10] 
Nucleotide sugar
 metabolism 
85.71 GALE 
GALT 
UGP2 
[11]-[13] 
Regulators of 
Bone 
Mineralization 
82.35 FURIN [14] 
Activation of 
Csk by cAMP-
dependent 
Protein Kinase 
Inhibits 
Signaling 
through the T 
Cell Receptor 
82.35 ALPL 
COL4A1 
COL4A2 
IBSP 
[15]-[18] 
Transcriptional 
activation of 
dbpb from 
mRNA 
82.35 NFKB1 
NFKBIA 
RELA 
[19]-[21] 
 
TABLE VI 
PATHWAYS FROM SVM-LASSO RANKED BY 10-FOLD CV CLASSIFICATION 
ACCURACY IN BREAST CANCER DATA. 
Pathway 10-fold CV 
accuracy (%) 
Selected 
genes 
Ref. 
Actions of 
Nitric Oxide 
in the Heart 
60 CYP7B1 
GOT2 
GOT1 
[24]- [25] 
Acute 
Myocardial 
Infarction 
60 ODC1 
OAC3 
[26]-[27] 
 
Table 6 shows the top pathways with the highest accuracy 
of 10-fold CV in breast cancer data. Next, the accuracy for 
both pathway is equal which is 60%.  For the first pathway 
in the table is Actions of Nitric Oxide in the Heart or known 
as Nitric oxide (NO) [28]. Nitric oxide (NO) is a pleiotropic 
regulator which critical to the numerous biological processes, 
include vasodilatation, neurotransmission, and macrophage-
mediated immunity. Also a multifunctional gaseous 
molecule and a highly reactive free radical [29]. Furthermore, 
various studies have shown the combination of three 
isoforms which are nitric oxide synthases (NOS), comprises 
inducible (iNOS), and endothelial NOS (eNOS) can promote 
or inhibit the etiology of cancer. Interestingly, NOS activity 
has been detected in tumor cells of various histogenetic 
origins. From this pathway, there are three informative genes 
are selected. These genes are validated with biology 
database that shows the relation with cancer diseases. 
Next pathway is Acute Myocardial Infarction, known as a 
myocardial infarction (MI). Which is proven its potential 
implications for cancer disease in women such as breast 
cancer. Previous research by Scottish Breast Cancer 
Committee found a significant reduction in the incidence of 
fatal myocardial infarction in women receiving adjuvant 
tamoxifen that can cause breast cancer [30].  Furthermore, 
not only in cancer, but it is also has been examined in 
chronic diseases like Heart disease and cancer in a 
population-based sample of middle-aged men [31]. This is 
supported with the informative selected genes by the 
proposed method that shown the relation with targeted 
phenotype.     
As a conclusion, both pathways have different 
information, different selected genes and different relation 
that gives a lot of clues towards cancer diseases. With this 
knowledge, it can help the expert to identify and detect the 
cancer diseases easily.  
IV. CONCLUSIONS 
Introduction of microarray technology has enabled the 
capability to measure the expression of several thousand of 
genes with multiple samples simultaneously. This has 
spurred the development of various sophisticated 
computational methods that used to analyse the microarray 
data and extract useful information from the data that can 
help us to understand the biology of the phenotype of study. 
However, the early methods of microarray analysis often 
based on the single-gene analysis (SGA), which analyze the 
data in terms of individual genes. Basically, the result of the 
analysis often in the form of a list of differentially expressed 
genes (DEGs), which consists of individual genes that found 
differentially expressed in the dataset. This list of DEGs 
often failed to provide mechanistic insights regarding the 
biology of the phenotype of study [32]. 
 This research focuses on the pathway-based analysis 
approach with support vector machine to improve gene 
selection and classification in cancer diseases. Pathway-
based analysis has been applied to the gene expression data. 
Support vector machine is a machine learning that applied 
the computational approach in classifying the genes based on 
their features. In support vector machine, penalizedSVM has 
been implemented for gene selection process.  
In this research, pathway-based analysis with support 
vector machine was introduced to predict the optimal gene 
classification result. In order to reduce the size of data, a 
LASSO algorithm has been used in support vector machine. 
There are two types dataset that used in this research which 
is lung cancer dataset and breast cancer dataset. Every gene 
expression data will be merged with pathway data. Thus, the 
process of selection and classification were done in sets of 
data. It can reduce the complexity of classification process 
and less time-consuming.  
As a result, the accuracy of gene selection is produced, 
and comparison between previous methods are being made. 
By using lung cancer data, the accuracy of classification was 
higher, but for breast cancer data the accuracy was low.  
This shows that the types of data affect the performance of 
classification. Next, the selected informative gene was 
analyzed using the biological database in order to study the 
relation or contribution to cancer disease.  
From the comparison, the accuracy performance of the 
proposed method was better in lung cancer data compared 
the previous methods. But for breast cancer data the 
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performance is not good as lung cancer data. As a 
conclusion, pathway-based analysis with support vector 
machine (LASSO) successfully classified the genes to 
improve the accuracy performance of gene selection and 
classification in cancer disease. 
After that, the performance measurement is done by 
calculating the accuracy performance and validate the gene 
selection with the biological database. The implement did 
improve the accuracy performance of gene selection and 
classification process.  The difference between previous 
works that used same data is more than 30%. This shows a 
good improvement to the current methods with an addition 
of pathway-based analysis in gene classification. As stated, 
the pathway-based analysis is the best analysis method in 
classification compared to previous methods. 
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